Filtros de búsqueda

Lista de obras de

ADARs, RNA editing and more in hematological malignancies

artículo científico publicado en 2020

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

scientific article published on 30 July 2018

BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.

artículo científico publicado en 2018

Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center

scientific article published on 09 January 2020

Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply

scientific article published on 29 March 2016

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

artículo científico publicado en 2017

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

artículo científico publicado en 2019

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

artículo científico publicado en 2017

Clinical implication of centrosome amplification in plasma cell neoplasm

artículo científico publicado en 2005

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

artículo científico publicado en 2006

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

artículo científico publicado en 2006

Immunoglobulin M Paraproteinaemias

artículo científico publicado en 2020

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

artículo científico publicado en 2020

Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing

scientific article published on 13 January 2020

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

article

Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma

artículo científico publicado en 2018

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)

artículo científico publicado en 2018

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

artículo científico publicado en 2017

STAT3: A Promising Therapeutic Target in Multiple Myeloma.

artículo científico publicado en 2019

Targeting NF-κB Signaling for Multiple Myeloma

artículo científico publicado en 2020

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

artículo científico publicado en 2006

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda